While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value. \
When it comes to AI, the consensus is that healthcare organizations have an opportunity right now to take an enterprise-wide approach that encompasses everything from workforce to infrastructure to governance and beyond. Here are these ten essential elements of an enterprise-wide AI strategy for healthcare organizations.
Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.
The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.
ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.